



IpA

IMMUNOPRECISE ANTIBODIES

# FY 2025 Q1

## Earnings Presentation



# Disclosures

## Disclaimer

This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company’s securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company’s potential cash generation performance in any way.

## Forward Looking Statements

This presentation includes forward-looking statements (within the meaning of applicable securities laws) to provide prospective investors with information pertaining to the Company’s long-term business objective. Forward-looking statements often, but not always, are identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeting” and “intend” and statements that an event or result “may”, “will”, “should”, “could”, or “might” occur or be achieved and other similar expressions.

Forward-looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company’s management about the Company’s business, planned acquisitions, future plans, anticipated events & other future conditions. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation.

The forward-looking statements that are contained in this presentation involve a number of risks and uncertainties and are based on certain assumptions, including but not limited to: the progress, timing and costs related to the execution of the Company’s business plan and strategy; estimates and projections regarding the industry in which the Company operates; the future success of research and development activities; the absence of material changes in general business and economic conditions; estimates regarding the future financing and capital requirements; and the absence of adverse changes in relevant laws and regulations. As a consequence, actual results might differ materially from results forecast or suggested in these forward-looking statements. Please see the Company’s most recent Annual Information Form, which is available under the Company’s profile on EDGAR at [www.sec.gov/edgar](http://www.sec.gov/edgar) and SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca) for additional related risks factors that could materially affect the Company’s operations and financial results.

Furthermore, forward-looking statements contained herein are made as of the date of this MD&A presentation and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise except as required by applicable securities. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.



# Fiscal Year 2025 Q1 Business Update

# AI-Enhanced Antibody Drug Discovery


## Business Model



### Pillar 1: Revenue based

LENS<sup>ai</sup> Data Analytics  
SaaS/API Revenue

Drug Discovery & Development  
Fee-for-Service Revenue



### Pillar 2: Licensing based

Assets, Collaborations  
and Partnerships  
(Milestones and  
Royalties)

**Competitive advantage: #1 globally ranked CRO<sup>1</sup> leveraging LENS<sup>ai</sup><sup>™</sup>, powered by HYFTs<sup>®</sup>**

1. ROOTS 2022, Antibody Discovery Services and Platforms Market (4th Edition), 2021-2035; pp.118

# Strategically built for innovation

Continued strong financial performance through advanced technology and deep experience



## Drug Discovery & Development Fee-for-Service



### Revenue driver:

Leveraging deep experience and success rates of technology

## LENS<sup>ai</sup> Data Analytics SaaS/API



### Technology driver:

Achieves significant milestone engineering antibodies *in silico*

## Assets, Collaborations and Partnerships



### Asset advancement:


Talem pipeline AI advancements

**Trusted by the best: 19** of top **20** pharma clients



# Fiscal Year 2025 Q1 Financial Update


# Quarterly Revenue




All values listed in CAD.

# Focus on Efficient Cost Management


Research & Development



Sales & Marketing



General & Administrative




All values listed in CAD.




# Net Loss of \$4M, equivalent to (\$0.15) per share (basic & diluted)

Net Loss





Earnings Per Share



All values listed in CAD.

## Ending Q1 Cash Balance of \$4M



All values listed in CAD.

# Q&A

Q1 FY 2025  
Earnings Call



September 16, 2024 | [ir.ipatherapeutics.com](http://ir.ipatherapeutics.com) | NASDAQ: IPA TSXV: IPA

©2024 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand is an independently operating subsidiary of ImmunoPrecise Antibodies. BioStrand, LENS<sup>®</sup> and HYFTS are trademarks of BioStrand, BV. Talem is an independently operating subsidiary of ImmunoPrecise Antibodies. Talem is a trademark of Talem Therapeutics LLC.

The HUB of  
Biotherapeutic  
Intelligence™